ArticleCell reports2013

Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors.

Michaela Waibel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.